Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286220 | 1.00 | GABRA5 (0.38) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2SNCA | |
| SCHEMBL286244 | 0.91 | L3MBTL1 (0.39) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2SNCA | |
| SCHEMBL286095 | 0.85 | GABRA5 (0.43) | GABRA5L3MBTL1GABRA1 | |
| SCHEMBL18091974 | 0.85 | GABRA5 (0.35) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18092035 | 0.85 | GABRA5 (0.35) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL285764 | 0.85 | GABRA5 (0.38) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL286245 | 0.84 | POLB (0.40) | L3MBTL1ALDH1A1SMN1; SMN2TP53GAA | |
| SCHEMBL2750501 | 0.82 | HCAR2 (0.38) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL285886 | 0.82 | L3MBTL1 (0.38) | GABRA5L3MBTL1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL285587 | 0.82 | ZAP70 (0.35) | GABRA5L3MBTL1ALDH1A1HDAC4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427459-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | claimed |
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-8178522-B2 | Thiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178522-B2 | Thiazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2427459-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127974-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286116-A1 | THIAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286116-A1 | THIAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286116-A1 | THIAZOLES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885L3MBTL1 4666/4885ALDH1A1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.